Insulin

Siddharth Mittal, CEO & MD, Biocon, elaborates on his plans to grow this business further

Pulitzer Prize winner Siddhartha Mukherjee's The Song of The Cell is a beautifully crafted exposition of the author's own lifelong fascination with the subject

Company left with low-margin brands in India after selling profitable ones

Glenmark Pharmaceuticals on Thursday said it has launched Thiazolidinedione Lobeglitazone in the country for the treatment of type 2 diabetes in adults. The Mumbai-based drug firm has launched the medication under the brand name LOBG and is priced at around Rs 10 per tablet. Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled Type 2 diabetes among insulin-resistant diabetic patients, Glenmark Pharmaceuticals said in a statement. The company had received approval from the Indian drug regulator, Drug Controller General of India, for manufacturing and marketing Lobeglitazone, based on a randomised, double-blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18 years and older. "As per the International Diabetes Federation, diabetes affects 74 million adults in India, of which, around 40 per cent of them seem to be insulin-resistant... "We are proud to introduce LOBG; an innovative an

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

In an interview, Arun Chandravarkar explains why a company must continue investing in R&D despite the impact on short-term Ebitda

The geopolitical incidents of the recent past as well as the pandemic have not really helped cost pressure: Tambe

Eris Lifesciences (Eris) is foraying into an oligopolistic insulin market with its own insulin brand this month

The company will respond to the CRL to satisfy the FDA's requests

President Joe Biden pledged that his social agenda legislation would deliver tangible savings on prescription drugs for all Americans

Semglee may now be substituted for Sanofi's Lantus by a pharmacist in the US

Biocon Biologics CEO says portfolio to form a substantial part of $1 bn revenue target, to roll out insulin Aspart by next year

Firm seen benefiting from operating leverage, biologic sales by FY22

Development takes Biocon a step closer to commercialise its glargine biosimilar Semglee in America

Wockhardt is present in emerging markets like Mexico, Brazil with insulins

The researchers synthesised an insulin analogue called glycoinsulin, and demonstrated that it can also lower blood glucose levels in preclinical studies

The Bengaluru-headquartered company believes Stelis could be a disruptor in insulin accessibility and affordability.

Biocon's ready-to-use pre-filled disposable pen with insulin Glargine is manufactured at its plant in Bengaluru

This is the latest in a series of setbacks in the research to find a less painful alternative to administer insulin

According to a new study, many patients were injecting insulin improperly, leading to worse glucose control, poorer outcomes and higher costs